Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Wolf-Henning Boehncke & Nicolò Costantino Brembilla. (2022) Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opinion on Biological Therapy 22:12, pages 1463-1473.
Read now
Read now
Articles from other publishers (20)
Laurent Peyrin-Biroulet, Jessica R. Allegretti, David T. Rubin, Brian Bressler, Matthew Germinaro, Kuan-Hsiang (Gary) Huang, Nicole Shipitofsky, Hongyan Zhang, Rebbecca Wilson, Chenglong Han, Brian G. Feagan, William J. Sandborn, Julian Panés, Tadakazu Hisamatsu, Gary R. Lichtenstein, Bruce E. Sands, Axel Dignass, Orest Abrahamovych, Halyna Afanasieva, Lilia Aitova, Engin Altintas, Romain Altwegg, Pavel Andreev, Kazuki Aomatsu, Monika Augustyn, Paola Balestrieri, Jakob Begun, Luciana Brunatto, Diego Bulgheroni, Elena Bunkova, Mercedes Cabello, Qian Cao, Flavio Caprioli, Rute Cerqueira, Baili Chen, Chou-Chen Chen, Chou-Pin Chen, Cheng-Tang Chiu, Chang Hwan Choi, Michele Cicala, Olena Datsenko, Pieter Dewint, Eugeni Domenech, Joris Dutré, George Duvall, Juan Fernandez, Rafal Filip, Ronald Fogel, Sharyle Fowler, Toshimitsu Fujii, Masayuki Fukata, Yohei Furumoto, Antonio Gasbarrini, Beata Gawdis-Wojnarska, Cyrielle Gilletta, Paolo Gionchetti, Eran Goldin, Oleksandr Golovchenko, Maciej Gonciarz, Can Gonen, Gaston Gonzalez Segura, Oleksii Gridnyev, Tibor Gyokeres, Xavier Hébuterne, Charlotte Hedin, Per Hellström, Ida Normiha Hilmi, Ivo Horný, Gyula Horvat, Namiko Hoshi, Ludek Hrdlicka, Shunji Ishihara, Olha Ivanishyn, Byung Ik Jang, Odery Junior, Takashi Kagaya, Shuji Kanmura, Marina Karakina, Nakai Katsuhiko, Jaroslaw Kierkus, Hyo Jong Kim, Tae-Oh Kim, Young-Ho Kim, Gyula G. Kiss, Jochen Klaus, Dariusz Kleczkowski, Maria Klopocka, Taku Kobayashi, Iwona Kobielusz-Gembala, Ja Seol Koo, Adam Kopon, Tetiana Kravchenko, Masatoshi Kudo, Kwang An Kwon, Paula Lago, David Laharie, Ian Lawrance, Jaroslaw Leszczyszyn, Yan Li, Milan Lukas, Christian Maaser, Atsuo Maemoto, Hiroyuki Marusawa, Matthew McBride, Shoba Mendu, Pal Miheller, Hideharu Miyabayashi, Wolfgang Mohl, Gregory Moore, Satoshi Motoya, Narayanachar Murali, Mohammed Naem, Koichi Nakajima, Yasunari Nakamoto, Stéphane Nancey, Joaquim Neto, Michio Onizawa, Yohei Ono, Yohei Ono, Taro Osada, Marina Osipenko, Danuta Owczarek, Bhaktasharan Patel, Kamal Patel, Elina Petrova, Elena Poroshina, Francisco Portela, Lyudmyla Prystupa, Monserrat Rivero, Xavier Roblin, Jacek Romatowski, Grazyna Rydzewska, Simone Saibeni, Hirotake Sakuraba, Mark Samaan, Michael Schultz, Joerg Schulze, Shahriar Sedghi, Ursula Seidler, Sung Jae Shin, Mykola Stanislavchuk, David Stokesberry, Takayoshi Suzuki, Hiroki Taguchi, Lyudmila Tankova, Lena Thin, Alexander Tkachev, Leyanira Torrealba, Nataliia Tsarynna, Zsolt Tulassay, Tetsuya Ueo, Ekaterina Valuyskikh, Olga Vasilevskaya, Manuel Viamonte, Shu-Chen Wei, Roni Weisshof, Katarzyna Wojcik, Byong Duk Ye, Hsu-Heng Yen, Hyuk Yoon, Kosuke Yoshida, Andriy Yurkiv, Osamu Zaha & Qiang Zhan. (2023) Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology 165:6, pages 1443-1457.
Crossref
Crossref
Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh & Joseph F. Merola. (2023) Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and Therapy 10:6, pages 1479-1501.
Crossref
Crossref
Eric Breinlinger, Stacy Van Epps, Michael Friedman, Maria Argiriadi, Ellen Chien, Gekleng Chhor, Marlon Cowart, Theresa Dunstan, Candace Graff, David Hardee, J. Martin Herold, Andrew Little, Richard McCarthy, Julie Parmentier, Matthew Perham, Wei Qiu, Michael Schrimpf, Thomas Vargo, Matthew P. Webster, Fei Wu, Dawn Bennett & Jeremy Edmunds. (2023) Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712. Journal of Medicinal Chemistry 66:20, pages 14335-14356.
Crossref
Crossref
L. Puig, E. Daudén, M. Cuervas‐Mons, C. Novella & C. Guisado. (2023)
Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The
SPRING
study
. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Yiying Xue, Husheng Mei, Yisa Chen, James D. Griffin, Qingsong Liu, Ellen Weisberg & Jing Yang. (2023) Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2. MedComm 4:3.
Crossref
Crossref
Nicolo Costantino Brembilla & Wolf-Henning Boehncke. (2023) Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Frontiers in Immunology 14.
Crossref
Crossref
Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng & Philip S. Helliwell. (2023)
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized,
Placebo‐Controlled DISCOVER
‐1 Study
. ACR Open Rheumatology 5:3, pages 149-164.
Crossref
Crossref
Philip J. Mease, Alexis Ogdie, Soumya D. Chakravarty, Natalie J. Shiff, Iris Lin, Robert R. McLean, Wendi Malley, Rebecca L. Spitzer, Arthur Kavanaugh & Joseph F. Merola. (2022) Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs - Real World Outcomes 9:4, pages 617-628.
Crossref
Crossref
Sophie Vieujean, Ferdinando D’Amico, Patrick Netter, Silvio Danese & Laurent Peyrin‐Biroulet. (2022) Landscape of new drugs and targets in inflammatory bowel disease. United European Gastroenterology Journal 10:10, pages 1129-1166.
Crossref
Crossref
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, Waleed Alshehhi, Humeira Badsha & Jamal Al‐Saleh. (2022) Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. International Journal of Rheumatic Diseases 25:10, pages 1107-1122.
Crossref
Crossref
Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Prasheen Agarwal, Feifei Yang, Alexa P. Kollmeier, Elizabeth C. Hsia, Natalie J. Shiff, Bei Zhou, Chenglong Han, May Shawi, William Tillett & Philip J. Mease. (2022) The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial. Advances in Therapy 39:10, pages 4613-4631.
Crossref
Crossref
Dongping Zhao, Liqin Liu, Xinlin Liu, Jinlei Zhang, Yuqing Yin, Linli Luan, Dingwen Jiang, Xiong Yang, Lei Li, Hualong Xiong, Dongming Xing, Qingbing Zheng, Ningshao Xia, Yuyong Tao, Shaowei Li & Haiming Huang. (2022) A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. Journal of Nanobiotechnology 20:1.
Crossref
Crossref
Alison McCallion, Danielle J. Sisnett, Katherine B. Zutautas, Donya Hayati, Katherine G. Spiess, Stanimira Aleksieva, Harshavardhan Lingegowda, Madhuri Koti & Chandrakant Tayade. (2022) Endometriosis through an immunological lens: a pathophysiology based in immune dysregulation. Exploration of Immunology, pages 454-483.
Crossref
Crossref
Ana G. Abril, Mónica Carrera, Vicente Notario, Ángeles Sánchez-Pérez & Tomás G. Villa. (2022) The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics. Antibiotics 11:5, pages 653.
Crossref
Crossref
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes & Atul Deodhar. (2022) Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open 8:1, pages e002195.
Crossref
Crossref
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Pérez-Gil, Fiorella Vasquez Chinchay & Manuel Galán-Gutiérrez. (2022) Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. F1000Research 11, pages 1178.
Crossref
Crossref
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Pérez-Gil, Fiorella Vasquez Chinchay & Manuel Galán-Gutiérrez. (2022) Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. F1000Research 11, pages 1178.
Crossref
Crossref
Wolf-Henning Boehncke. (2021) Psoriasisarthritis: Relevantes für die dermatologische PraxisPsoriatic arthritis: important aspects for the dermatological practice. Der Hautarzt 72:11, pages 946-952.
Crossref
Crossref
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair, Wolf-Henning Boehncke & Christopher Ritchlin. (2021) Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology 60:5, pages 2109-2121.
Crossref
Crossref
Kazuya Nagano & Yasuo Tsutsumi. (2021) Phage Display Technology as a Powerful Platform for Antibody Drug Discovery. Viruses 13:2, pages 178.
Crossref
Crossref